Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. develops therapeutics that target galectin proteins, with its lead program focused on belapectin, a carbohydrate-based galectin-3 inhibitor for MASH cirrhosis and portal hypertension. Company updates commonly cover NAVIGATE clinical-trial results, biomarker analyses, medical-conference presentations, journal publications, and FDA communications related to the belapectin development program.
News also includes financial results, research and development spending, cash-resource updates, credit financing, board composition, and investor or key-opinion-leader events. Galectin has also described additional development interests in combination immunotherapy for advanced head and neck cancers and other malignancies.
Galectin Therapeutics (NASDAQ:GALT) reported Q1 2026 results and a belapectin program update. Net loss was $5.1 million ($0.08/share), improved from $9.6 million in Q1 2025. Cash was $14.1 million, plus $10 million available under a credit line, which the company believes funds operations through May 2027.
In the NAVIGATE Phase 2b/3 trial in MASH cirrhosis, belapectin 2 mg/kg showed statistically significant reductions in liver stiffness and fewer patients with >30% increases vs placebo. Upcoming catalysts include EASL 2026 data presentations and an FDA Type-C meeting in Q2 2026.
Galectin Therapeutics (NASDAQ:GALT) reported publication of Phase 2b NAVIGATE trial results for galectin-3 inhibitor belapectin in Journal of Hepatology. The study in patients with MASH cirrhosis and portal hypertension showed belapectin 2 mg/kg reduced new esophageal varices numerically versus placebo, with statistical significance in the per-protocol population and supportive fibrosis/portal hypertension biomarkers, alongside a favorable safety profile.
Galectin Therapeutics (NASDAQ: GALT) reported 2025 results and a business update highlighting progress on belapectin for MASH cirrhosis and portal hypertension.
Key facts: R&D expenses fell to $14.3M, net loss improved to $31.0M, cash of $17.7M plus a $10M credit line extends runway to April 2027. NAVIGATE showed per-protocol varices reductions and multiple supportive biomarker signals; an FDA meeting is planned Q2 2026.
Galectin Therapeutics (NASDAQ:GALT) appointed Henry Brem, M.D., as an independent director on March 17, 2026. Dr. Brem is a neurosurgeon-scientist from Johns Hopkins with extensive translational-medicine experience, NIH funding over four decades, 416+ peer-reviewed papers, patents, and membership in the National Academy of Medicine.
This addition aims to strengthen clinical and regulatory expertise as Galectin advances belapectin for patients with MASH cirrhosis and portal hypertension.
Galectin Therapeutics (NASDAQ:GALT) will host a virtual key opinion leader event on March 10, 2026 at 12:00 PM ET to discuss belapectin development for MASH cirrhosis and portal hypertension.
The event features KOLs Naga P. Chalasani, MD and Naim Alkhouri, MD, and will highlight updated NAVIGATE Phase 3 results and include a live Q&A.
Galectin Therapeutics (NASDAQ:GALT) reported an FDA written response to its Type C meeting request on belapectin, noting alignment on the proposed registration-trial patient population and prior agreement to use a centralized, blinded endoscopy review for variceal assessment.
The company will request a follow-up Type C meeting to finalize unresolved trial-design components and present recently generated biomarker data from the AASLD meeting. Separately, chairman Richard E. Uihlein provided a new $10 million unsecured, convertible line of credit and extended existing convertible facilities to June 30, 2027, supporting cash sufficiency through at least March 2027.
Galectin Therapeutics (NASDAQ: GALT) reported Q3 2025 results and a clinical update on belapectin from the NAVIGATE trial presented at AASLD. The company submitted the NAVIGATE data package to the FDA and expects feedback by year-end. Key 18-month biomarker findings showed reductions in liver stiffness (FibroScan), ELF, PRO-C3, YKL-40, and improvements in Baveno VII portal hypertension categories, with the 2 mg/kg dose showing a shift to no/low-risk CSPH (42.0% to 56.8%).
Q3 cash was $11.5M, a $10M chairman line of credit was added July 8, 2025, R&D was $2.6M, G&A $1.6M, and net loss was $8.2M (−$0.13/share).
Galectin Therapeutics (NASDAQ:GALT) presented NAVIGATE Phase 2b results for belapectin in 355 patients with compensated MASH cirrhosis and portal hypertension at AASLD 2025.
Key findings: randomization 1:1:1 to IV belapectin 2 mg/kg, 4 mg/kg or placebo every other week for 78 weeks; ELF >11.3 new varices 22.7% (2 mg/kg) vs 42.9% (placebo); Pro-C3 mean change at 78 weeks: –6.4 ng/mL (2 mg/kg) vs –4.5 ng/mL (placebo); sustained reduction in new varices persisted through 36 months (cumulative incidence 12.4% for 2 mg/kg vs 23.4% placebo). Safety profile comparable to placebo.
Galectin Therapeutics (NASDAQ: GALT) will present at the H.C. Wainwright 9th Annual MASH Virtual Investor Conference on October 21, 2025.
Company presentation is scheduled for October 21, 2025 at 7:00 AM ET, with a live webcast and archived replay available on the company’s Events & Presentations page in Investors. Management attending includes Joel Lewis, CEO, and Khurram Jamil, M.D., CMO, who will be available for one-on-one meetings during the conference; interested investors should contact their H.C. Wainwright representative to arrange meetings.
Galectin Therapeutics (NASDAQ: GALT) will present new clinical data from the NAVIGATE trial at the AASLD Liver Meeting 2025 in Washington, DC, November 7-11, 2025. The company will deliver one oral presentation and one poster highlighting belapectin results in MASH cirrhosis and portal hypertension.
Oral: "Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months" on Nov 10, 2025, 2:00–3:30 PM ET (Abstract 0145). Poster: "Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months" on Nov 8, 2025, 8:00 AM–5:00 PM ET (Abstract 2375). Presentations will be viewable by AASLD attendees and posted on the company's Events & Presentations page after the congress.